Oric Pharmaceuticals’ (ORIC) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Oric Pharmaceuticals (NASDAQ:ORIC) in a report released on Thursday,Benzinga reports. HC Wainwright currently has a $25.00 target price on the stock.

Other equities analysts also recently issued research reports about the company. Oppenheimer reissued an “outperform” rating and set a $15.00 price target on shares of Oric Pharmaceuticals in a research report on Tuesday, February 24th. Wall Street Zen raised Oric Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Wedbush dropped their price objective on Oric Pharmaceuticals from $20.00 to $17.00 and set an “outperform” rating for the company in a research report on Wednesday. Piper Sandler began coverage on shares of Oric Pharmaceuticals in a research note on Wednesday, January 7th. They issued an “overweight” rating and a $22.00 target price for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Oric Pharmaceuticals in a research note on Monday, March 9th. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $19.90.

Oric Pharmaceuticals Price Performance

Shares of NASDAQ ORIC opened at $8.89 on Thursday. The business’s 50 day moving average is $11.50 and its two-hundred day moving average is $11.29. Oric Pharmaceuticals has a 52-week low of $3.90 and a 52-week high of $14.93. The firm has a market cap of $892.20 million, a price-to-earnings ratio of -5.85 and a beta of 1.36.

Oric Pharmaceuticals (NASDAQ:ORIC) last announced its quarterly earnings results on Monday, February 23rd. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.04. Analysts anticipate that Oric Pharmaceuticals will post -2.17 EPS for the current fiscal year.

Insider Activity at Oric Pharmaceuticals

In related news, CFO Dominic Piscitelli sold 52,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 24th. The shares were sold at an average price of $13.51, for a total value of $702,520.00. Following the completion of the sale, the chief financial officer owned 68,148 shares of the company’s stock, valued at $920,679.48. This trade represents a 43.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 6.82% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ORIC. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Oric Pharmaceuticals by 26.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,732 shares of the company’s stock valued at $39,000 after buying an additional 977 shares during the period. California State Teachers Retirement System lifted its stake in shares of Oric Pharmaceuticals by 3.9% in the 4th quarter. California State Teachers Retirement System now owns 33,959 shares of the company’s stock valued at $278,000 after purchasing an additional 1,270 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Oric Pharmaceuticals by 2.9% in the 2nd quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 49,000 shares of the company’s stock worth $497,000 after purchasing an additional 1,358 shares during the last quarter. ProShare Advisors LLC grew its stake in shares of Oric Pharmaceuticals by 12.9% during the third quarter. ProShare Advisors LLC now owns 13,383 shares of the company’s stock worth $161,000 after purchasing an additional 1,527 shares during the period. Finally, The Manufacturers Life Insurance Company increased its holdings in Oric Pharmaceuticals by 1.6% in the fourth quarter. The Manufacturers Life Insurance Company now owns 128,649 shares of the company’s stock valued at $1,042,000 after purchasing an additional 1,985 shares during the last quarter. 95.05% of the stock is currently owned by institutional investors and hedge funds.

Oric Pharmaceuticals News Roundup

Here are the key news stories impacting Oric Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reaffirmed a “buy” and set a $25 price target (large upside vs. current levels), providing a constructive analyst endorsement that can support longer-term upside. HC Wainwright Reaffirms Buy
• Positive Sentiment: Unusual options activity: traders bought ~2,266 call options (≈2,058% above normal), signaling short-term speculative bullish interest or hedging ahead of catalysts. (No article)
• Neutral Sentiment: Company granted inducement awards (80,000 stock options + 15,000 RSUs) to a new non‑executive employee — modest potential dilution but standard for new hires. Inducement Grants Filing
• Neutral Sentiment: Broader biotech headlines (e.g., BiopharmaDive roundup) are creating a mixed sector backdrop but are not ORIC‑specific drivers. Biotech News Roundup
• Negative Sentiment: ORIC shares fell sharply after early‑stage prostate cancer trial updates showed concerning side‑effect signals and prompted critical sell‑side commentary; multiple outlets report the move and investor selling. These clinical safety notes are the principal near‑term negative catalyst for the stock. Trial Data & Stock Drop
• Negative Sentiment: Analyst pressure: Wedbush lowered expectations for ORIC and subsequent coverage noted an analyst downgrade that coincided with a gap down in shares — further downward pressure from reduced sell‑side conviction. Wedbush Lowers Expectations Shares Gap Down After Downgrade

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.